PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy

PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy

This study was conducted to investigate whether polymorphisms of genes involved in immune checkpoints can predict the clinical outcomes of patients with advanced stage non-small cell lung cancer (NSCLC) after 1st line paclitaxel-cisplatin chemotherapy. A total of 379 NSCLC patients were enrolled. Tw...

Full description

Bibliographic Details
Main Authors: Lee, Shin Yup, Jung, Deuk Kju, Choi, Jin Eun, Jin, Cheng Cheng, Hong, Mi Jeong, Do, Sook Kyung, Kang, Hyo-Gyoung, Lee, Won Kee, Seok, Yangki, Lee, Eung Bae, Jeong, Ji Yun, Shin, Kyung Min, Yoo, Seung Soo, Lee, Jaehee, Cha, Seung Ick, Kim, Chang Ho, Park, Jae Yong
Format: Online
Language:English
Published: Nature Publishing Group 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867646/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867646/

Similar Items